Expression of Bruton's tyrosine kinase in B-cell neoplasms evaluated by flow cytometry.

Natália Aydos Marcondes, Flavo Beno Fernandes, Ana Paula Alegretti, Gustavo Adolpho Moreira Faulhaber

Abstract read

In one paragraph

Article in Clinical and experimental medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.4field-weighted citation impact, top 31% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Natália Aydos MarcondesPrograma de Pós Graduação em Medicina: Ciências Médicas, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2400, 2° andar, Porto Alegre, 90035-903, Brazil. nam_nati@yahoo.com.br.

Flavo Beno FernandesLaboratório Zanol, Rua Mostardeiro 333 sala 120, Porto Alegre, 90430-001, Brazil.

Ana Paula AlegrettiUnidade de Diagnóstico Personalizado, Serviço de Patologia Clínica, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2350, Porto Alegre, 90035-903, Brazil.

Gustavo Adolpho Moreira FaulhaberPrograma de Pós Graduação em Medicina: Ciências Médicas, Universidade Federal do Rio Grande do Sul, Rua Ramiro Barcelos 2400, 2° andar, Porto Alegre, 90035-903, Brazil.

Universidade Federal do Rio Grande do Sul · BRHospital de Clínicas de Porto Alegre · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bruton's tyrosine kinase (BTK) is a cytoplasmatic protein that is part of the B-cell antigen receptor signaling pathway. Our aim was to evaluate the expression of BTK in B-cell neoplasms and compare it to normal B-cell lymphocytes. After surface staining with CD19 and CD45, flow cytometry staining for intracellular BTK was performed in leukemic or mature B-cells from bone marrow or peripheral blood samples. No differences in BTK expression were identified between groups, or in comparison to control samples, there was no association between BTK expression and the clinical variables evaluated. BTK expression in B-cell neoplasms was similar to that of normal B-cell lymphocytes.

Indexed as

AdolescentAdultAgammaglobulinaemia Tyrosine KinaseAgedAged, 80 and overFemaleFlow CytometryHumansLymphoma, B-CellMaleMiddle AgedProtein-Tyrosine KinasesYoung AdultAgammaglobulinaemia Tyrosine KinaseBTK protein, humanProtein-Tyrosine KinasesB-cell neoplasmBruton’s tyrosine kinaseBTKFlow cytometry

Identifiers

PMID28028621

DOI10.1007/s10238-016-0447-9

OpenAlexW2562890971

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.